Downstream STING pathways IRF3 and NF-κB differentially regulate CCL22 in response to cytosolic dsDNA

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Cytosolic double-stranded DNA (dsDNA) triggers immune responses via type I interferons.
• Cancer immunotherapies can activate cytosolic nucleic acid sensing pathways.
• Regulatory T cells (Tregs) in tumors suppress anti-tumor immunity.

Purpose of the Study:

• To investigate the effect of cytosolic dsDNA on CCL22 expression in malignant cells.
• To identify the transcription factors mediating dsDNA-induced CCL22 upregulation.
• To understand the implications for cancer immunotherapy.

Main Methods:

• Introduction of dsDNA into malignant cells.
• Analysis of CCL22 and interferon (IFN) expression.
• Investigation of transcription factor involvement (IRF3, NF-κB) and STING pathway activation.
• Comparison of dsDNA response in different cell line strains.

Main Results:

• Cytosolic dsDNA robustly upregulates CCL22 expression.
• CCL22 upregulation is primarily mediated by IRF3, not NF-κB.
• dsDNA also upregulates type I interferon beta (IFN-β).
• Cell line strain variation exists in dsDNA-induced CCL22 and IFN-β upregulation.

Conclusions:

• IRF3 plays a key role in dsDNA-induced CCL22 upregulation, contrary to expectations.
• The findings suggest potential for immune modulation in cancer therapy.
• Tumor evolution may alter cancer cells' capacity to respond to dsDNA sensing.